Literature DB >> 10200333

Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis.

T M Timiryasova1, B Chen, P Haghighat, I Fodor.   

Abstract

The use of vaccinia virus vectors for cancer gene therapy may become a powerful method to achieve efficient anti-tumor effects. We used recombinant vaccinia virus expressing wild-type p53 (rVV-p53) to examine the biological effects of exogenous tumor suppressor p53 in human (U-373MG, U-87MG, LN-Z308) and rat glioma cells (9L, C6) in vitro. All glioma cell lines infected with rVV-p53 exhibited growth inhibition and underwent apoptosis as demonstrated by morphological studies using nuclear staining and flow cytometry. The key role of p53 in cell growth inhibition was confirmed as measured by colony forming efficiency. Growth inhibition and apoptosis were independent of the endogenous p53 status of the glioma cell lines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200333     DOI: 10.3892/ijo.14.5.845

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

Review 1.  Oncolytic viral therapy of malignant glioma.

Authors:  Jacqueline Nuss Parker; David F Bauer; James J Cody; James M Markert
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

2.  Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.

Authors:  Juraj Hlavaty; Gerrit Jandl; Melissa Liszt; Helga Petznek; Marielle König-Schuster; Jenny Sedlak; Monika Egerbacher; Jakob Weissenberger; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  J Neurooncol       Date:  2010-07-11       Impact factor: 4.130

Review 3.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01

4.  Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses.

Authors:  Béla Dénes; Jie Yu; Nadja Fodor; Zsuzsanna Takátsy; István Fodor; William H R Langridge
Journal:  Mol Biotechnol       Date:  2006-11       Impact factor: 2.695

Review 5.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

6.  Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Authors:  B T Ober; P Brühl; M Schmidt; V Wieser; W Gritschenberger; S Coulibaly; H Savidis-Dacho; M Gerencer; F G Falkner
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 7.  [The use of p53 as a tool for human cancer therapy].

Authors:  V P Almazov; D V Kochetkov; P M Chumakov
Journal:  Mol Biol (Mosk)       Date:  2007 Nov-Dec

8.  Gene therapy trials for the treatment of high-grade gliomas.

Authors:  Adam M Sonabend; Ilya V Ulasov; Maciej S Lesniak
Journal:  Gene Ther Mol Biol       Date:  2007

9.  Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses.

Authors:  P F McAuliffe; W R Jarnagin; P Johnson; K A Delman; H Federoff; Y Fong
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.267

10.  Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Authors:  Andrea Worschech; Nanhai Chen; Yong A Yu; Qian Zhang; Zoltan Pos; Stephanie Weibel; Viktoria Raab; Marianna Sabatino; Alessandro Monaco; Hui Liu; Vladia Monsurró; R Mark Buller; David F Stroncek; Ena Wang; Aladar A Szalay; Francesco M Marincola
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.